Advertisement
Screener

KYMERA THERAPEUTICS, INC. (KYMR) Graph

KYMR Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $65.00M; Cost of revenue $65.00M; Research and development $119.48M; Operating expenses $140.61M.
  • 2026-03-31: Revenue $34.37M; Cost of revenue $34.37M; Research and development $98.16M; Operating expenses $118.52M.
  • 2025-12-31: Revenue $2.87M*; Cost of revenue $2.87M*; Research and development $83.83M*; Operating expenses $100.77M*.
  • 2025-09-30: Revenue $2.76M; Cost of revenue $2.76M; Research and development $74.09M; Operating expenses $95.28M.

Type Of Arrangement

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

KYMR revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Gilead Agreement$45.00MRevenue$65.00MCost of revenue$65.00MOperating expenses$140.61MOperating income-$75.61MOther income, net$14.40MResearch & development$119.48MNet income-$61.21M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$65.00M$65.00M$119.48M$140.61M(m)-$61.21M
2026-03-31$34.37M$34.37M$98.16M$118.52M(m)-$69.23M
2025-12-31$2.87M*$2.87M*$83.83M*$100.77M*(m)$535.72M*
2025-09-30$2.76M$2.76M$74.09M$95.28M(m)-$82.17M
2025-06-30$11.48M$11.48M$78.39M$96.03M(m)-$76.61M
2025-03-31$22.10M$22.10M$80.25M$96.53M(m)-$65.58M
2024-09-30$3.74M$3.74M$60.41M$75.86M(m)-$62.49M
2024-06-30$25.65M$25.65M$59.20M$76.58M(m)-$42.06M
2024-03-31$10.29M$10.29M$48.82M$68.12M(m)-$48.56M
2023-09-30$4.73M(m)$48.12M$62.24M$100.00K-$52.87M
2023-06-30$16.51M(m)$45.77M$59.90M$100.00K-$38.80M
2023-03-31$9.47M(m)$42.23M$54.79M$0.00-$40.93M
2022-09-30$9.55M(m)$43.88M$54.43M$0.00-$43.00M
2022-06-30$11.51M(m)$41.29M$52.32M$0.00-$40.26M
2022-03-31$9.62M(m)$35.94M$46.55M$0.00-$36.68M
2021-09-30$20.34M(m)$38.31M$48.97M$0.00-$28.58M
2021-06-30$18.52M(m)$35.22M$43.25M$0.00-$24.66M
2021-03-31$18.70M(m)$25.96M$31.87M$0.00-$13.07M
2020-09-30$14.53M(m)$15.78M$22.62M$0.00-$7.99M
2020-06-30$3.29M(m)$13.82M$17.48M$0.00-$13.99M
2020-03-31$3.43M(m)$12.12M$14.68M$0.00-$10.93M
2019-09-30$950.00K(m)$11.31M$12.81M$0.00-$11.42M

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$99.36M$99.36M$217.64M$259.13M(m)-$130.44M
2025-06-30$33.58M$33.58M$158.64M$192.56M(m)-$142.19M
2024-06-30$35.94M$35.94M$108.02M$144.69M(m)-$90.62M
2023-06-30$25.98M(m)$87.99M$114.69M$100.00K-$79.73M
2022-06-30$21.14M(m)$77.24M$98.88M$0.00-$76.94M
2021-06-30$37.22M(m)$61.18M$75.12M$0.00-$37.73M
2020-06-30$6.72M(m)$25.93M$32.16M$0.00-$24.92M

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2025-09-30$36.34M$36.34M$232.74M$287.84M(m)-$224.37M
2024-09-30$39.68M$39.68M$168.43M$220.56M(m)-$153.11M
2023-09-30$30.71M(m)$136.11M$176.93M$200.00K-$132.59M
2022-09-30$30.69M(m)$121.11M$153.31M$0.00-$119.94M
2021-09-30$57.56M(m)$99.49M$124.09M$0.00-$66.32M
2020-09-30$21.25M(m)$41.71M$54.77M$0.00-$32.91M
2019-09-30$1.10M(m)$26.07M$31.52M$0.00-$29.73M

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31$39.21M$39.21M$316.57M$388.61M$0.00$311.35M
2024-12-31$47.07M$47.07M$240.25M$308.71M(m)$223.86M
2023-12-31$78.59M$78.59M$189.08M$244.12M(m)$146.96M
2022-12-31$46.83M$46.83M$164.25M$208.08M$0.00$154.81M
2021-12-31$72.83M(m)$137.02M$173.36M$0.00$100.22M
2020-12-31$34.03M(m)$62.10M$80.34M$0.00-$45.59M
2019-12-31$2.93M(m)$37.16M$45.14M$0.00-$41.25M

Similar stocks

Stock NameCountryMarket CapPE Ratio
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
REPLIGEN CORP (RGEN)United States$10.755B185.31
Vaxcyte, Inc. (PCVX)United States$8.466B-7.91
BIO-TECHNE Corp (TECH)United States$11.379B74.68
Twist Bioscience Corp (TWST)United States$11.540B-47.21
Immunovant, Inc. (IMVT)United States$7.028B-14.78
HALOZYME THERAPEUTICS, INC. (HALO)United States$13.083B21.59
CG Oncology, Inc. (CGON)United States$6.095B-27.95
Scholar Rock Holding Corp (SRRK)United States$5.920B-16.37